Jain Abhishek, Singam Amol, Mudiganti V N K Srinivas
Critical Care Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Cureus. 2024 Mar 31;16(3):e57309. doi: 10.7759/cureus.57309. eCollection 2024 Mar.
Sepsis remains a critical healthcare challenge, characterized by dysregulated immune responses to infection, leading to organ dysfunction and high mortality rates. Traditional treatment strategies often fail to address the underlying immune dysregulation, necessitating exploring novel therapeutic approaches. Immunomodulatory therapy holds promise in sepsis management by restoring immune balance and mitigating excessive inflammation. This comprehensive review examines the pathophysiology of sepsis, current challenges in treatment, and recent advancements in immunomodulatory agents, including biologics, immunotherapy, and cellular therapies. Clinical trial outcomes, safety profiles, and future research and clinical practice implications are discussed. While immunomodulatory therapies show considerable potential in improving sepsis outcomes, their successful implementation requires further research, collaboration, and integration into standard clinical protocols.
脓毒症仍然是一个严峻的医疗挑战，其特征是对感染的免疫反应失调，导致器官功能障碍和高死亡率。传统治疗策略往往无法解决潜在的免疫失调问题，因此需要探索新的治疗方法。免疫调节疗法有望通过恢复免疫平衡和减轻过度炎症来治疗脓毒症。这篇综述全面探讨了脓毒症的病理生理学、当前治疗面临的挑战以及免疫调节药物（包括生物制剂、免疫疗法和细胞疗法）的最新进展。文中还讨论了临床试验结果、安全性概况以及对未来研究和临床实践的启示。虽然免疫调节疗法在改善脓毒症治疗效果方面显示出巨大潜力，但其成功应用仍需要进一步研究、合作，并纳入标准临床方案。
